This study is dedicated to addressing the lack of research on the most effective dosage of long-acting growth hormone for children with short stature. By employing clinical trial design, we are committed to investigating the therapeutic benefits and safety profiles associated with varying doses of long-acting growth hormone. Our ultimate goal is to offer clinicians more precise treatment guidance and assist patients in attaining optimal growth and developmental outcomes.
Patients with short stature or a genetic target height below 2 standard deviations;
Individuals who are pre-pubertal (Tanner stage I) and pubertal (Tanner stages II-IV).
Legal guardians consenting to participate in the study and signing informed consent forms.
Known or suspected hypersensitivity reactions to the investigational product or related products;
Presence of severe systemic diseases;
Patients with malignant tumors;
Participation in any other clinical trial and receipt of drug or non-drug interventions within the 3 months prior to screening;